Ergoteles’s Assembly Biosciences ASMB Stock Holding History

Ergoteles’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,050	Closed	-$421K	–	1192
2021 Q2	$421K	Buy	+9,050	New	+$448K	0.01%	888

Other funds holding ASMB

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Ergoteles's ASMB Position: Q3 2021 in Review

Ergoteles sold out of Assembly Biosciences (ASMB) in Q3 2021, closing a stake of 9,050 shares — an estimated $421K sold.

Ergoteles first reported a position in ASMB in Q2 2021 and held it in 1 quarter. The position peaked at $421K in Q2 2021. 65 funds tracked by Wall St. Rank hold ASMB as of Q3 2021.

Ergoteles reported no remaining Assembly Biosciences position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 9,050 Assembly Biosciences shares in Q3 2021, an estimated $421K.
Ergoteles first reported a position in Assembly Biosciences in Q2 2021 and held it in 1 quarter.
Ergoteles's Assembly Biosciences position peaked at $421K in Q2 2021.
65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.